2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13217A
    Vanoxerine 67469-69-6
    Vanoxerine (GBR-12909) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine (GBR-12909) binds to the target site on the dopamine transporter (DAT).
    Vanoxerine
  • HY-13225A
    Rivanicline 15585-43-0
    Rivanicline (RJR-2403; (E)-Metanicotine) is a neuronal nicotinic receptor (neuronal nicotinic receptor) agonist that is highly selective for the α4β2 subtype,Ki is 26 nM, which is more than 1000 times more inhibitory than α7 receptor.
    Rivanicline
  • HY-134358
    Ara-F-NAD+ 133575-27-6
    Ara-F-NAD+ is an arabino analogue of NAD+. Ara-F-NAD+ is a potent, reversible and slow-binding CD38 NADase inhibitor.
    Ara-F-NAD+
  • HY-135026
    DL-Norepinephrine tartrate 3414-63-9
    DL-Norepinephrine tartrate is a neurotransmitter, which targets adrenergic receptors, and causes large-amplitude sleep-like electrical activity in the neocortex and suppresses electroencephalography (EEG) activity in the hippocampus. DL-Norepinephrine tartrate results in head shake, difficulty walking, and frequent posture changes in rats model.
    DL-Norepinephrine tartrate
  • HY-135237
    DB04760 analog 1 2728373-94-0 99.87%
    DB04760 analog 1 is an analogue of DB04760.
    DB04760 analog 1
  • HY-136674
    Aftin-5 1461717-05-4
    Aftin-5 is an inducer for Amyloid-β 42 (Aβ42). Aftin-5 upregulates Aβ42 and downregulates Aβ38 levels in a β-secretase- and γ-secretase-dependent manner by altering the ultrastructure of mitochondria. Aftin-5 exhibits slightly cytotoxicity in cell SH-SY5Y, HT22, N2a and N2a-AβPP695, with IC50s of 180, 194, 178 and 150 μM, respectively.
    Aftin-5
  • HY-137494
    Ethyl β-carboline-3-carboxylate 74214-62-3 99.75%
    Ethyl β-carboline-3-carboxylate (fl-CCE) is a ligand and short-acting antagonist of benzodiazepine receptors. Ethyl β-carboline-3-carboxylate did not affect cerebellar cGMP levels when used alone, but when taken together with Diazepam, it significantly inhibited the cGMP levels that were upregulated by Diazepam.
    Ethyl β-carboline-3-carboxylate
  • HY-13866A
    Ro 31-8220 125314-64-9
    Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7.
    Ro 31-8220
  • HY-139347
    Mazisotine 1638588-92-7 99.09%
    SSTR4 agonist-1 (Compound 47) is a selective agonist for somatostatin receptor subtype 4 (SSTR4) with an EC50 of 4.7 nM. SSTR4 agonist-1 reveals a half-life > 130 minutes in human liver microsomes.
    Mazisotine
  • HY-141554
    Dihydrotetrabenazine 3466-75-9 99.23%
    Dihydrotetrabenazine (DHTBZ) is the active metabolite of Tetrabenazine (HY-B0590). Dihydrotetrabenazine is the inhibitor for human vesicular monoamine transporter 2 (VMAT2), that reduces monoamine content in presynaptic neurons, and can be used in movement disorder research.
    Dihydrotetrabenazine
  • HY-14536A
    Methylene blue (purity≥70%) 61-73-4
    Methylene blue (purity≥70%) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue (purity≥70%) is a vasopressor and is often used as a dye in several medical procedures. Methylene blue (purity≥70%) through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue (purity≥70%) is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue (purity≥70%) is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
    Methylene blue (purity≥70%)
  • HY-14538R
    Haloperidol (Standard) 52-86-8
    Haloperidol (Standard) is the analytical standard of Haloperidol. This product is intended for research and analytical applications. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
    Haloperidol (Standard)
  • HY-14542A
    Ziprasidone hydrochloride 122883-93-6
    Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist. Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
    Ziprasidone hydrochloride
  • HY-14544R
    Quetiapine (Standard) 111974-69-7
    Quetiapine (Standard) is the analytical standard of Quetiapine. This product is intended for research and analytical applications. Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects.
    Quetiapine (Standard)
  • HY-147517
    Keap1-Nrf2-IN-9 2769963-24-6 98.52%
    Keap1-Nrf2-IN-9 (compound 11) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein protein interaction) inhibitor with an IC50 of 0.575 μM. Keap1-Nrf2-IN-9 increases the expression of Nrf2 target genes including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and glutamate-cysteine ligase catalytic (Gclc) and modulatory (Gclm) subunits. Keap1-Nrf2-IN-9 shows not cytotoxic activity in ARPE19 cells.
    Keap1-Nrf2-IN-9
  • HY-15069A
    Fanapanel hydrate 1255517-78-2 99.76%
    Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
    Fanapanel hydrate
  • HY-15129R
    O-Phospho-L-serine (Standard) 407-41-0
    O-Phospho-L-serine (Standard) (L-Serine O-phosphate (Standard)) is the analytical standard of O-Phospho-L-serine (HY-15129). This product is intended for research and analytical applications. O-Phospho-L-serine is the immediate precursor to L-cystein in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8). O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2.
    O-Phospho-L-serine (Standard)
  • HY-15238A
    ST-836 hydrochloride 1415564-68-9 98.11%
    ST-836 hydrochloride (compound 34) is a potent dopamine receptor ligand with Ki values of 4.5 nM, 132 nM for D3 and D2, respectively. ST-836 hydrochloride has the potential for Parkinson’s disease.
    ST-836 hydrochloride
  • HY-15414R
    Vortioxetine (Standard) 508233-74-7
    Vortioxetine (Standard) is an analytical standard for Vortioxetine. This product is intended for research and analytical applications. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM).
    Vortioxetine (Standard)
  • HY-155938
    Cyano-myracrylamide 2801702-34-9 98.0%
    Cyano-myracrylamide is an inhibitor of zinc finger DHHC domain-containing palmitoyltransferase 20 (zDHHC20) with an IC50 value of 1.35 µM. Cyano-myracrylamide also inhibits the S-Acylation of EGFR and CD36. Cyano-myracrylamide also inhibits S-acylation of Legionella E3 ligase GobX, MyD88, and Ras, which are substrates of zDHHC20, zDHHC9, and zDHHC6, respectively, in HEK293T cells expressing recombinant Legionella GobX, recombinant human MyD88, or endogenous Ras.
    Cyano-myracrylamide
Cat. No. Product Name / Synonyms Application Reactivity